Business Wire

Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for ...

CAMBRIDGE, Mass. & HOBOKEN, N.J.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Science today announced that VOWST™ (fecal microbiota spores, live-brpk) is now ...
Seeking Alpha

Seres: VOWST Is A Great Product But Commercialization Prospects Unclear Due To Very High Price

Seres Therapeutics launched VOWST for recurrent C. difficile infection in early June, in partnership with Nestle Health. VOWST represents a significant improvement over current standard of care.
Business Wire

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced preliminary key VOWST (fecal microbiota spores, live-brpk) launch ...
BioWorld

Seres wins FDA nod for Vowst in recurrent C. difficile infection

As expected, Seres Therapeutics Inc. gained U.S. FDA approval of the BLA for the oral microbiome therapeutic Vowst, formerly known as SER-109, for prevention of recurrent Clostridium difficile ...
Medical Xpress

New treatment for recurrence of C. difficile infection approved by FDA

The U.S. Food and Drug Administration (FDA) has approved VOWST, a microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibacterial treatment for ...
Nasdaq

Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWSTTM (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in ...

“Since being founded by Flagship Pioneering over a decade ago, Seres has led the development of microbiome therapeutics, and today’s FDA approval of VOWST as the first orally administered ...
Pharm Exec

FDA Approves Microbiome Therapeutic Vowst to Prevent Recurrence of C. difficile Infections in Adults

Seres Therapeutics and Nestlé Health Science celebrate the FDA's approval of Vowst, a first-of-its-kind orally administered microbiota-based therapeutic set to transform the lives of patients with ...
Healio

FDA approves Vowst as first oral microbiota biotherapeutic for recurrent C. difficile

Please provide your email address to receive an email when new articles are posted on . “The availability of a fecal microbiota product that can be taken orally is a significant step forward in ...
Seeking Alpha

Seres Therapeutics: Microbiome Therapeutics Amid High Operational Costs And Uncertain Profitability Path

Seres Therapeutics and Nestlé Health Science received FDA approval for VOWST, a drug to prevent recurrent C. difficile infection, triggering a $125M payment from Nestlé to Seres. Seres reported a Q1 ...
gizmodo

FDA Approves Poop-Based Pill to Treat Hardy Gut Infections

The healing powers of poop can now officially come in a more palatable pill. This week, the Food and Drug Administration approved the drug Vowst, an oral capsule packed with beneficial bacteria ...
Business Insider

Orsini Specialty Pharmacy Now Dispensing VOWST™ (fecal microbiota spores, live - brpk) Capsules for Oral Administration for the Prevention of Recurrence of C. Difficile ...

ELK GROVE VILLAGE, Ill., June 22, 2023 /PRNewswire/ -- Orsini Specialty Pharmacy announced today that Aimmune Therapeutics has selected it as a limited distribution partner for VOWST™ (fecal ...
Nasdaq

Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported financial results for the third quarter ended September 30, 2023, ...